Due to bleak forecasts regarding performance, 녹십자 is plummeting.
As of 9:45 a.m. on the 17th, 녹십자 is trading at 146,700 won, down 9.16% from the previous day.
On the same day, DB Financial Investment analyzed that 녹십자’s consolidated revenue for the previous quarter, last year's fourth quarter, would be 450.9 billion won, with an operating loss of 6.6 billion won.
Lee Myung-sun, a researcher at DB Financial Investment, said, "On a separate basis, sales of high-revenue vaccines and treatments are expected to decrease due to the drop in respiratory infection rates," and added, "The U.S. subsidiary is expected to incur an operating loss due to failure to meet revenue targets amid sluggish patient recruitment in the U.S. Copay Program." The increase in research and development costs at the subsidiary is also considered a negative factor.
However, this researcher expressed optimism regarding this year's performance. He added, "With an increase in flu patients in the first quarter, the rapid recovery of prescription drug sales and the Copay Program targeting existing patients will lead U.S. 알리글로 to achieve its revenue goals."